secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xilio Therapeutics, Inc. (XLO)
CIK:        0001840233
Form:       8-K
Filed at:   2025-06-12T23:59:59+00:00
Accession:  0001558370-25-008571
Event type: other_material
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Xilio stockholders elect Class I directors, approve 3x share increase and officer exculpation
--------------------------------------------------------------------------------

- René Russo (32.5M), Sara Bonstein (32.4M), James Shannon (31.0M) elected Class I directors.
- Share increase amendment approved: 38.8M for (95.1%), increasing authorized common from 200M to 600M shares; filed June 10.
- Officer exculpation amendment approved: 32.3M for (99.3%); filed June 10.
- Ernst & Young ratified as auditor for FY2025: 40.7M for (99.7%).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840233/000155837025008571/0001558370-25-008571-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840233/000155837025008571/xlo-20250610x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-008571

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer